Versatile Dyversity System at Leading European Cancer Research Centre
News May 07, 2010
Syngene has announce its Dyversity multi-application image analyzer is being used by scientists in The Cancer Research UK Cambridge Research Institute (CRI) at the University of Cambridge, one of Europe’s major cancer research hubs, to accelerate the pace of research on proteins and DNA associated with a variety of different cancers.
Researchers at The Cancer Research UK Cambridge Research Institute (CRI) are using a Dyversity system to accurately analyze fluorescent and chemiluminescent Western blots labelled with various Qdot®s and ECL respectively. They are also using the system to image agarose gels containing DNA stained with SYBR® Safe DNA gel stain.
The information from the gels and blots is being used to map genes and proteins associated with cancers and is helping scientists at the CRI to provide data, which could lead to the development of new therapies for these life threatening diseases.
The Dyversity system installed at the CRI contains a high-resolution 16 bit, CCD camera with intelligent control software specifically for chemiluminescence. Additionally, their system has a computer controlled lens that moves simultaneously with the motorized sample stage. This ensures the Dyversity can focus to produce high quality images with perfect contrast, without any of the time consuming trial and error imaging usually associated with capturing images of chemiluminescent blots.
Dr Jane Gray, Senior Scientific Officer at the Cancer Research UK Cambridge Research Institute, said: “Since we have such a diverse range of cancer projects ongoing at the institute we need an imager that offers versatility and flexibility. We saw the Dyversity system at a proteomics meeting and were impressed by the Versatile Dyversity System number of different applications it could be used for. We reviewed it alongside another imager and found that the GeneSnap software and iChemi processor were really easy to use, which is why we decided this was the right system for us.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE